Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shugan Shunqi Wan is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Chongqing Searainbow Pharmaceutical Co., Ltd., specifically indicated for the treatment of functional dyspepsia and symptoms related to liver qi stagnation. The formula is composed of several botanical ingredients, including Bupleurum, Cyperus, and Bitter Orange, which work collectively to regulate gastrointestinal motility and alleviate epigastric pain and abdominal distension. Pharmacologically, it is thought to modulate gastrointestinal hormones such as motilin and gastrin, as well as serotonergic pathways, to restore normal digestive function and relieve qi stagnation in the liver and stomach.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shugan shunqi wan.